Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group

Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group

Annals of Oncology ◽

10.1093/annonc/mdh469 ◽

2004 ◽

Vol 15 (12) ◽

pp. 1816-1824 ◽

Cited By ~ 56

Author(s):

P. Schöffski ◽

S. Riggert ◽

P. Fumoleau ◽

M. Campone ◽

O. Bolte ◽

...

Keyword(s):

Drug Development ◽

Phase I ◽

Solid Tumors ◽

Phase I Trial ◽

European Organization ◽

New Drug ◽

New Drug Development ◽

The intravenous administration of rViscumin induces cytokine release and antibody formation. Results of EORTC New Drug Development Group trial 16002

10.1016/s0959-8049(02)81169-8 ◽

2002 ◽

Vol 38 ◽

pp. S154

Keyword(s):

Drug Development ◽

Intravenous Administration ◽

Antibody Formation ◽

Cytokine Release ◽

New Drug ◽

New Drug Development ◽

Development Group ◽

Group Trial

A study from the EORTC new drug development group: Open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer

10.1016/j.ejca.2005.07.030 ◽

2006 ◽

Vol 42 (2) ◽

pp. 200-204 ◽

Cited By ~ 12

Author(s):

W. Fiedler ◽

N. Tchen ◽

J. Bloch ◽

P. Fargeot ◽

R. Sorio ◽

...

Keyword(s):

Prostate Cancer ◽

Drug Development ◽

Phase Ii ◽

Phase Ii Study ◽

Hormone Refractory Prostate Cancer ◽

Open Label ◽

Open Label Phase ◽

New Drug Development ◽

Hormone Refractory ◽

Population Pharmacokinetics And Pharmacodynamics

Population Pharmacokinetics and Pharmacodynamics of Doxorubicin and Cyclophosphamide in Breast Cancer Patients

Clinical Pharmacokinetics ◽

10.2165/00003088-200746120-00005 ◽

2007 ◽

Vol 46 (12) ◽

pp. 1051-1068 ◽

Cited By ~ 30

Author(s):

Markus Joerger ◽

Alwin D R Huitema ◽

Dick J Richel ◽

Christian Dittrich ◽

Nikolas Pavlidis ◽

...

Keyword(s):

Breast Cancer ◽

Population Pharmacokinetics ◽

Cancer Patients ◽

Breast Cancer Patients ◽

Pharmacokinetics And Pharmacodynamics ◽

Entry and evaluation of elderly patients in european organization for research and treatment of cancer (EORTC) new-drug–development studies

Cancer ◽

10.1002/1097-0142(19950715)76:2<333::aid-cncr2820760226>3.0.co;2-i ◽

1995 ◽

Vol 76 (2) ◽

pp. 333-338 ◽

Cited By ~ 78

Author(s):

Silvio Monfardini ◽

Roberto Sorio ◽

Guido Hoctin Boes ◽

Stan Kaye ◽

Diego Serraino

Keyword(s):

Drug Development ◽

Elderly Patients ◽

Development Studies ◽

European Organization ◽

New Drug ◽

New Drug Development

Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group

10.1016/s0959-8049(03)00629-4 ◽

2003 ◽

Vol 39 (16) ◽

pp. 2334-2340 ◽

Cited By ~ 33

Author(s):

E Briasoulis ◽

N Pavlidis ◽

C Terret ◽

J Bauer ◽

W Fiedler ◽

...

Keyword(s):

Pancreatic Cancer ◽

Drug Development ◽

Phase Ii ◽

Phase Ii Trial ◽

Advanced Pancreatic Cancer ◽

Line Treatment ◽

First Line ◽

New Drug Development ◽

Development Group ◽

First Line Treatment

A Clinical Trial Model for Intraperitoneal Drug Development: A Phase 0 Post-Op Study of Intravenous Ketorolac in Ovarian Cancer Patients

Gynecologic Oncology ◽

10.1016/j.ygyno.2016.08.278 ◽

2016 ◽

Vol 143 (1) ◽

pp. 209

Author(s):

J Coffey ◽

T. Rutledge ◽

S. Adams ◽

M. Gaede ◽

L. Hudson ◽

...

Keyword(s):

Ovarian Cancer ◽

Clinical Trial ◽

Drug Development ◽

Cancer Patients ◽

Phase 0 ◽

Intravenous Ketorolac

Contributions to Oncology - Relevance of Tumor Models for Anticancer Drug Development ◽

New Anticancer Agents Developed by the New Drug Development Group (AWO)

10.1159/000425848 ◽

1999 ◽

pp. 361-367 ◽

Cited By ~ 1

Author(s):

B. K. Keppler ◽

G. Eisenbrand ◽

M. A. Jakupec

Keyword(s):

Drug Development ◽

Anticancer Agents ◽

New Drug ◽

New Drug Development ◽

Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials

10.1016/s0959-8049(00)00369-5 ◽

2001 ◽

Vol 37 (1) ◽

pp. 47-53 ◽

Cited By ~ 65

Author(s):

A Cull ◽

S Howat ◽

E Greimel ◽

A.-C Waldenstrom ◽

J Arraras ◽

...

Keyword(s):

Quality Of Life ◽

Ovarian Cancer ◽

Clinical Trials ◽

Cancer Patients ◽

European Organization

Multicentre phase II study of imatinib mesylate in patients with recurrent anaplastic oligodendroglioma (AOD)/mixed oligoastrocytoma (MOA) and anaplastic astrocytoma (AA)/low grade astrocytoma (LGA): An EORTC New Drug Development Group (NDDG) and Brain Tumor Group (BTG) study

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.1517 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 1517-1517 ◽

Cited By ~ 8

Author(s):

M. van den Bent ◽

A. Brandes ◽

M. Frenay ◽

P. Fumoleau ◽

R. Stupp ◽

...

Keyword(s):

Brain Tumor ◽

Drug Development ◽

Imatinib Mesylate ◽

Anaplastic Astrocytoma ◽

Phase Ii Study ◽

Low Grade ◽

Multicentre Phase ◽

Tumor Group ◽

New Drug Development ◽